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Background: Pyoderma gangrenosum (PG) is a rare inflammatory disease presenting
with chronic-recurrent cutaneous ulcers histopathologically hallmarked by neutrophilic
infiltrates, which may occur more frequently at sites of surgical traumas. The disease is
habitually limited to the skin, but it can virtually involve any organ. Nevertheless, no prior
cases of PG involving the thyroid bed have ever been reported.
Case Report: A bilateral PG of the breast was diagnosed in a 51-year-old woman and
treated with intravenous methylprednisolone pulse-therapy and cyclosporine, with partial
improvement. During the hospitalization, cytological examination of two hypoechoic
thyroid nodules by fine-needle aspiration (FNA) was consistent with thyroid carcinoma.
After total thyroidectomy, histopathology confirmed a papillary thyroid cancer (PTC), and
radioactive iodine ablation was performed. At 12-month ultrasonographic follow-up, two
hypoechoic avascular areas localized in the empty thyroid bed raised the suspect of PTC
recurrence. However, (i) undetectable levels of thyroglobulin without anti-thyroglobulin
antibodies, (ii) neutrophilia and increased inflammatory marker levels, and (iii) cytological
examination of FNA showing numerous neutrophils induced to suspect thyroid bed
PG infiltration. An ex juvantibus approach with high-dose methylprednisolone led to
dimensional reduction of the hypoechoic areas on ultrasonography, thus confirming the
hypothesis of thyroid bed PG.
Conclusion: This case of thyroid bed PG supports the idea that PG reflects a
cutaneous phenotype encompassed in the spectrum of systemic neutrophilic diseases.
Endocrinologists should be aware that thyroid bed PG involvement is an albeit rare
differential diagnosis to consider in patients who had undergone thyroid surgery,
especially with a history of PG.
Keywords: pyoderma gangrenosum, differentiated thyroid carcinoma, papillary thyroid carcinoma, pathergy,
thyroidectomy
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INTRODUCTION
Papillary thyroid carcinoma (PTC), the main variant of
differentiated thyroid carcinoma (DTC), is the most common
thyroid cancer, accounting for 70–80% of all thyroid carcinomas
and occurring predominantly in women, generally with a good
prognosis (1). PTC is characterized by a steady and continuous
increase in the incidence rate, which has more than doubled
within the past three decades all over the world (2).
Pyoderma gangrenosum (PG) is a rare chronic-relapsing
inflammatory disease clinically characterized by single or
multiple skin ulcers with undermined erythematous-violaceous
borders usually developing on the lower extremities (3). It is
nowadays regarded as autoinflammatory in origin and classified
in the spectrum of the so-called neutrophilic dermatoses,
which are a group of conditions hallmarked by accumulation
of mature neutrophils in the skin (4–6). Albeit rarely, in
this disease almost any organ system can be involved by
sterile neutrophilic infiltrates, with the lungs being the most
commonly affected site (3, 4). This condition may be idiopathic
or associated with underlying disorders, notably inflammatory
bowel diseases, rheumatological forms or neoplasms, particularly
FIGURE 1 | Dermatological and histopathological characteristics of pyoderma gangrenosum. (a,b) Ulcerative lesions showing necrotic base and
erythematous-violaceous undermined borders on the right and left breast, respectively; (c) Skin histology revealing epidermal necrosis and a dermal-hypodermal
inflammatory infiltrate mainly consisting of neutrophils (haematoxylin-eosin, original magnification ×100) (in the box, a magnified detail of the inflammatory infiltrate);
(d,e) Partial healing after therapy with pulsed intravenous methylprednisolone, followed by the combination of prednisone and cyclosporine given orally;
(f,g) Complete healing with hypertrophic aspects.
of lymphoreticular origin (3, 4). PG is typically accompanied
by a skin hyperreactivity leading to the pathergy phenomenon,
which is the occurrence of disease manifestations at sites of
traumas, either accidental or surgical ones (3, 7).
Herein, we report an extraordinary case of a female patient
with PG manifesting as classic ulcerative skin lesions associated
with a mass in an empty thyroid bed after total thyroidectomy
for PTC. This extracutaneous infiltrate mimicked a recurrence
of PTC on ultrasound (US) examination, making challenging the
diagnosis and management of this unique case.
MATERIALS AND METHODS
Serum thyroglobulin (Tg) levels were measured by
electrochemiluminescence sandwich immunoassay (ECLIA,
Elecsys Tg II, Roche R©, Mannheim, Germany) with an analytic
sensitivity of 0.04 ng/ml. Serum anti-Tg antibodies levels were
measured by fluorescence enzyme immunoassay (EliA; Thermo
Fisher Scientific, Life Technologies Italia R©, Monza, Italy;
normal <40 IU/ml). Thyroid ultrasound was performed at
each time of follow-up using a 14–16-MHz linear probe by the
same endocrinologist.
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Skin biopsy including both the edge and bed of the ulcer
was performed. The skin specimen was fixed in 10% buffered
formalin, embedded in paraffin, and sectioned into 3-µm
sections that were stained with haematoxylin-eosin.
Written informed consent was obtained from the patient for
the publication of this case report and any potentially-identifying
images and/or information.
CASE DESCRIPTION
A 51-year-old woman was hospitalized for the occurrence of
two bilateral painful skin ulcers with undermined, erythematous-
violaceous edges in the mammary region, which had begun 6
months before and had rapidly developed from pustular lesions
(Figures 1a,b). The skin lesions were refractory to antiseptic and
antibiotic therapies which had been administered in another
dermatology department.
Skin biopsy showed a dermal-hypodermal neutrophilic
infiltrate, suggesting PG (Figure 1c). Laboratory work-up ruled
out any underlying inflammatory condition. Pulse-therapy with
intravenous methylprednisolone 125mg daily for 5 consecutive
days was given with clinical improvement, followed and followed
by prednisone at progressively tapering dosages in combination
with cyclosporine 300mg daily, inducing progressive healing
of the lesions (Figures 1d–g). During hospitalization, chest
computerized tomography revealed a multinodular goiter. Neck
US disclosed a 12.4mm solid hypoechoic nodule in the upper
pole of the left thyroid lobe, and another 8.5mm hypoechoic
nodule in the lower pole of the same lobe. Fine-needle
aspiration (FNA) of the dominant nodule was performed, and
the cytological exam resulted in Tir4 category according to 2014
SIAPEC (Società Italiana di Anatomia Patologica) classification,
equivalent to “suspicious for thyroid carcinoma” (8). A total
thyroidectomy was performed, and the histological examination
was consistent with multicentric classical PTC, with focal
extension to extra-thyroidal soft tissues and surgical resection
margins. Histopathologic stadium was pT3(m)Nx according to
AJCC (American Joint Committee on Cancer) TNM VII Edition
Staging System (9).
Postoperatively, she received radioactive iodine ablation
treatment with 3700 MBq under human recombinant α-
thyrotropin stimulation (Thyrogen R©). The post-treatment
Whole Body Scan showed no uptake outside the thyroid bed.
The stimulated Tg serum value was 2.6 ng/ml.
Given these findings, the patient was classified at intermediate
risk of recurrence according to 2015 ATA score system. Due to
the neoplasm, cyclosporine was replaced by immunomodulating
therapy with dapsone, without recurrence of skin manifestations.
As shown in Table 1, at the 6-month follow-up examination,
there was no clinical, biochemical or US evidence of
tumor persistence or recurrence. Serum Tg concentrations
were undetectable during replacement thyroxine therapy
(unstimulated Tg measured several times by an high-sensitive
assay always <0.04 ng/mL) in the absence of interfering anti-Tg
antibodies. However, US examination of the neck performed
12 months after thyroid surgery revealed two hard hypoechoic
avascular areas with irregular margins in the thyroid bed, which
measured 16mm and 15mm in their maximum diameter,
respectively (Figure 2). No suspicious lymph nodes were
detected. Serum Tg levels were still undetectable, with negative











6 months after radioiodine
ablation
2.1 <0.04 <12 N/A N/A N/A No suspicious lesions in the thyroid
bed, no suspicious lymph nodes
12 months after radioiodine
ablation
0.89 <0.04 <12 60 1.17 3.22 Two hypoechoic avascular areas with
irregular margins in the thyroid bed,
16mm and 15mm in their maximum
diameter, respectively; no suspicious
lymph nodes
One week after pulse
intravenous
methylprednisolone
0.085 <0.04 <12 28 0.6 7.02 The two hypoechoic avascular areas
in the thyroid bed reduced to
10.9mm and 15mm in their
maximum diameter, respectively; no
suspicious lymph nodes
One month after pulse
intravenous
methylprednisolone
N/A N/A N/A Normal Normal Normal The two hypoechoic areas furtherly
reduced to 8.6mm and 9.2mm in
their maximum diameter, respectively;
no suspicious lymph nodes
Ten months after pulse
intravenous
methylprednisolonea
1.59 <0.04 <12 N/A N/A N/A The two hypoechoic areas are no
more visible in the thyroid bed; no
suspicious lymph nodes
TSH, Thyroid Stimulating Hormone; Tg, thyroglobulin, analytic sensitivity 0.04 ng/ml; Anti-Tg antibodies, anti-thyroglobulin antibodies, analytic sensitivity 12 IU/mL; ESR, Erythrocyte
Sedimentation Rate, normal values <20mm; CRP, C-Reactive Protein, normal values < 0.5 mg/dl; N/A, not available.
aDuring current therapy with oral prednisone and cyclosporine.
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FIGURE 2 | Neck ultrasonography performed at 12-month follow-up visit after thyroidectomy. (a) Transversal scan shows two adjacent left paratracheal lesions
(arrows). These marked hypoechoic areas have ill-defined margins but not microcalcifications; (b) Longitudinal scan depicts the elongated shape of the paratracheal
lesion (lateral one) and its parallel orientation to the dermis without deformation of surrounding tissues, unlike true focal masses.
anti-Tg antibodies. FNA of the two above-mentioned lesions
was performed under the impression of PTC recurrence; the
cytologic specimen revealed numerous neutrophils, together
with scattered erythrocytes, lymphocytes, histiocytes, and few
thyrocytes without cytological alterations. Gram staining as well
as bacterial and mycobacterial cultures of the FNA specimen
were negative. Blood exams revealed increased inflammatory
markers and neutrophilia.
The clinical, biochemical and cytological clues were consistent
with PG infiltration of the thyroid bed. Therefore, the
patient underwent again pulse therapy with intravenous
methylprednisolone under a strict US follow-up. Following
steroid treatment, the two cervical lesions appeared to be
dramatically reduced on neck US (with one lesion passing from
10.9mm in maximum diameter after the first week, to 8.6mm
after 1 month; the second cervical area passed from 15 to 9.2mm
in maximum diameter at the same time points). Both lesions
mentioned above were nomore visible after 10months (Figure 3)
confirming thyroid bed involvement by PG.
DISCUSSION
Detecting a mass in the thyroid bed of a patient who had a
past medical history of PG and thyroid cancer raises both the
possibility of relapse of PG or local recurrence of PTC. PG of the
thyroid bed has not been previously reported, and on ultrasound
imaging the morphology of PG lesions appeared very similar
to thyroid tissue. Essential clues for differentiating deep tissue
localization of PG and a recurrence of PTC on US is the parallel
orientation of the former, the absence of bright echogenic spots,
the elongated and poorly defined borders and its proximity to a
skin PG wound (7, 10).
To explain the exceptional association of these two different
diseases, different pathogenetic hypotheses may be postulated.
Firstly, PG can be a paraneoplastic manifestation of an
underlying tumor, particularly haematolymphoid malignancies
(11). However, DTC is rarely related to paraneoplastic syndromes
FIGURE 3 | Neck ultrasonography performed at 10-month follow-up visit after
the second cycle of intravenous methylprednisolone treatment shows
complete regression of the two hypoechoic areas in the thyroid bed.
(12, 13), and in the present case PG relapsed upon reaching
complete remission of PTC, thusmaking the relation between PG
and PTC unlike in our patient.
Common genetic basis may alternatively be involved.
Germline mutations in different genes involved in the innate
immune response have been identified in autoinflammatory
diseases (4). Similarly, a number of somatic mutations have been
found to occur in DTC (14). However, the cellular pathways
involved in the two conditions look different, and it is difficult
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to support a common monogenic basis. Nevertheless, dedicated
studies in this field are lacking, and we cannot definitely exclude
that a polygenic background may eventually predispose to
both conditions.
Finally, a conceivable hypothesis to explain the occurrence
of PG at the thyroid bed following surgery for PTC is
represented by the pathergy phenomenon. Pathergy consists
in the development of new skin lesions or the aggravation
of existing ones after trauma (15). Pathergy has a pivotal
role in inducing new post-surgical skin PG in patients with a
preexisting diagnosis of PG. However, while cutaneous PG has
been frequently reported after surgical procedures involving the
skin, especially breast surgery (16), visceral PG involvement
is usually not related to previous surgery. This may be due
to the fact that visceral PG is a very rare condition and
its diagnosis may be difficult to reach. On the other hand,
cases of visceral PG secondarily involving the skin have been
reported, as in a patient with lung PG mimicking a lung
carcinoma who, 3 months after a sleeve lobectomy and chest-
wall resection, developed skin PG ulcers at the site of the surgical
wound (17).
Therefore, we suppose that pathergy phenomenon may have
contributed to the development of post-surgical visceral PG, even
though its exact pathogenesis is still elusive. This case report
reinforces the concept that PG may be regarded as a neutrophilic
systemic disease, which may be associated with infiltration of
sterile neutrophilic infiltration of internal organs (4). The rare
extracutaneous neutrophilic involvement in PG (18), has been
mainly described as culture-negative pulmonary lesions, but also
bone, joint, central nervous system, spleen, kidney, and digestive
tract involvements have been reported (18).
A role for radioiodine therapy in this context is not defined,
as no specific association between PG and radioiodine has been
reported so far.
There have been many reports of non-thyroidal lesions
which can be mistaken for thyroid lesions on US (10).
However, although it has never been reported that a PG
asymptomatic localization might mimic a recurrent thyroidal
lesion, establishing the correct diagnosis is crucial, since PG
could be exacerbated by an unnecessary surgical intervention
potentially leading to pathergy. On the other hand, surgery
or radioactive iodine ablation would have been the first-choice
treatments if a thyroid cancer recurrence had been ascertained.
In conclusion, a multidisciplinary approach is needed
to correctly diagnose and manage these rare cases of
extracutaneous PG.
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